Top Markets
Coin of the day
Eli Lilly Eli Lilly

Eli Lilly

LLY
Rang in aandelen #15
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals... Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Aandeelprijs
$910.55
Marktkapitalisatie
$860.30B
Verandering (1 dag)
0.44%
Verandering (1 jaar)
5.28%
Land
US
Handel Eli Lilly (LLY)

Categorie

Operationele marge voor Eli Lilly (LLY)
Operationele marge op March 2026 TTM: 45.56%
Volgens de meest recente financiële rapporten en aandelenkoers van Eli Lilly is de huidige operationele marge (TTM) 45.56%. Eind 2024 had het bedrijf een operationele marge van 38.86%.
Geschiedenis van de operationele marge van Eli Lilly van 2000 tot 2026
Operationele marge aan het einde van elk jaar
Jaar Operationele Marge Wijzigen
2026 (TTM) 45.56% 0.00%
2025 45.56% 17.24%
2024 38.86% 22.94%
2023 31.61% 4.25%
2022 30.32% 8.25%
2021 28.01% -4.66%
2020 29.38% 9.30%
2019 26.88% -4.14%
2018 28.04% 31.77%
2017 21.28% 16.67%
2016 18.24% 1.33%
2015 18.00% 6.07%
2014 16.97% -29.29%
2013 24.00% 8.16%
2012 22.19% -14.69%
2011 26.01% -11.38%
2010 29.35% 0.62%
2009 29.17% 7.52%
2008 27.13% 5.24%
2007 25.78% -1.94%
2006 26.29% 5.54%
2005 24.91% -5.64%
2004 26.40% -5.14%
2003 27.83% -7.36%
2002 30.04% -7.03%
2001 32.31% -1.40%
2000 32.77% 0.00%
Operationele marge van vergelijkbare bedrijven of concurrenten
Bedrijf Operationele Marge Verschil in operationele marge Land
23.28% -99.49%
GB
27.17% -99.40%
US
26.72% -99.41%
US
31.24% -99.31%
CH
41.19% -99.10%
US
Wat is de Operationele marge van een bedrijf?
De Operationele marge is een belangrijke indicator om de winstgevendheid van een bedrijf te beoordelen. Hogere operationele marges zijn over het algemeen beter omdat ze aangeven dat een bedrijf zijn producten of diensten veel duurder kan verkopen dan de productiekosten. De Operationele marge wordt berekend door de winst van een bedrijf te delen door de omzet.